Published in Nanotechnology on November 11, 2009
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
More effective nanomedicines through particle design. Small (2011) 1.80
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. J Control Release (2013) 1.46
Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano (2011) 1.38
Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci U S A (2013) 1.37
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
A microfluidics approach towards high-throughput pathogen removal from blood using margination. Biomicrofluidics (2012) 1.23
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol Pharm (2012) 1.13
Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv (2010) 1.13
Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B Mater Biol Med (2013) 1.10
Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) (2014) 1.07
In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm (2010) 1.05
Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett (2014) 1.04
Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano (2012) 1.03
Dynamic factors controlling targeting nanocarriers to vascular endothelium. Curr Drug Metab (2012) 1.02
The Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter Nanorods. Adv Healthc Mater (2015) 1.01
The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology (2011) 1.00
A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS One (2013) 0.99
Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. Int J Radiat Oncol Biol Phys (2015) 0.96
Design rules for nanomedical engineering: from physical virology to the applications of virus-based materials in medicine. J Biol Phys (2013) 0.94
Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat Nanotechnol (2016) 0.93
Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev (2014) 0.91
Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X. Acta Biomater (2015) 0.90
Shaping bio-inspired nanotechnologies to target thrombosis for dual optical-magnetic resonance imaging. J Mater Chem B Mater Biol Med (2015) 0.89
Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett (2014) 0.85
Microfluidic system for facilitated quantification of nanoparticle accumulation to cells under laminar flow. Ann Biomed Eng (2012) 0.85
Multistage vector (MSV) therapeutics. J Control Release (2015) 0.84
Interaction between drug delivery vehicles and cells under the effect of shear stress. Biomicrofluidics (2015) 0.83
Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications. Chin Sci Bull (2012) 0.83
USNCTAM perspectives on mechanics in medicine. J R Soc Interface (2014) 0.83
The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. Biomaterials (2014) 0.82
Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res (2015) 0.82
Particle margination and its implications on intravenous anticancer drug delivery. AAPS PharmSciTech (2014) 0.81
Emergence and Utility of Nonspherical Particles in Biomedicine. Ind Eng Chem Res (2015) 0.81
Plasma protein corona modulates the vascular wall interaction of drug carriers in a material and donor specific manner. PLoS One (2014) 0.81
Shape matters: the diffusion rates of TMV rods and CPMV icosahedrons in a spheroid model of extracellular matrix are distinct. Biomater Sci (2013) 0.81
Cell and nanoparticle transport in tumour microvasculature: the role of size, shape and surface functionality of nanoparticles. Interface Focus (2016) 0.81
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Detection and imaging of aggressive cancer cells using an epidermal growth factor receptor (EGFR)-targeted filamentous plant virus-based nanoparticle. Bioconjug Chem (2015) 0.80
Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer. J Nanobiotechnology (2016) 0.79
Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.79
Internalization of red blood cell-mimicking hydrogel capsules with pH-triggered shape responses. ACS Nano (2014) 0.79
Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles. PLoS One (2015) 0.78
Size of the nanovectors determines the transplacental passage in pregnancy: study in rats. Am J Obstet Gynecol (2011) 0.77
Shape Control in Engineering of Polymeric Nanoparticles for Therapeutic Delivery. Biomater Sci (2015) 0.77
To Target or Not to Target: Active vs. Passive Tumor Homing of Filamentous Nanoparticles Based on Potato virus X. Cell Mol Bioeng (2015) 0.76
Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems. Ther Deliv (2015) 0.76
Size Dependent Kinetics of Gold Nanorods in EPR Mediated Tumor Delivery. Theranostics (2016) 0.76
Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B Mater Biol Med (2016) 0.75
Direct Tracking of Particles and Quantification of Margination in Blood Flow. Biophys J (2016) 0.75
Vascular targeting of nanoparticles for molecular imaging of diseased endothelium. Adv Drug Deliv Rev (2016) 0.75
Rescue of mitochondrial function in parkin-mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes. Neurosci Lett (2016) 0.75
Patient-specific computational modeling and magnetic nanoconstructs: tools for maximizing the efficacy of stem cell-based therapies. Methodist Debakey Cardiovasc J (2013) 0.75
Serum albumin 'camouflage' of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics. Biomaterials (2016) 0.75
Potato virus X, a filamentous plant viral nanoparticle for doxorubicin delivery in cancer therapy. Nanoscale (2017) 0.75
A Bayesian hierarchical model for maximizing the vascular adhesion of nanoparticles. Comput Mech (2014) 0.75
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep (2013) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08
Cells preferentially grow on rough substrates. Biomaterials (2010) 1.08
Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07
Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging (2004) 1.04
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation (2003) 1.02
Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging (2012) 1.02
Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release (2005) 1.02
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Modulating cellular adhesion through nanotopography. Biomaterials (2009) 0.99
A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery. Lab Chip (2010) 0.99
Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A (2012) 0.99
A low-voltage electrokinetic nanochannel drug delivery system. Lab Chip (2011) 0.99
A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS One (2013) 0.99
Adhesion of microfabricated particles on vascular endothelium: a parametric analysis. Ann Biomed Eng (2004) 0.99
Fractionation of serum components using nanoporous substrates. Bioconjug Chem (2006) 0.98
Mesoporous silica as a membrane for ultra-thin implantable direct glucose fuel cells. Lab Chip (2011) 0.98
Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res (2006) 0.98
Design maps for the hyperthermic treatment of tumors with superparamagnetic nanoparticles. PLoS One (2013) 0.98
Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry (2010) 0.96
The margination propensity of spherical particles for vascular targeting in the microcirculation. J Nanobiotechnology (2008) 0.95
Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small (2012) 0.95
Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94
Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration. Pharm Res (2010) 0.94
Abdominal aortic aneurysm: contrast-enhanced US for missed endoleaks after endoluminal repair. Radiology (2004) 0.94